S-1/A: Acurx Pharmaceuticals Seeks $22.9 Million in Public Offering to Advance Antibiotic Pipeline

Acurx Pharmaceuticals is offering 12,019,230 shares of common stock to raise approximately $22.9 million for working capital and clinical trials.

Summary

• Acurx Pharmaceuticals, a late-stage biopharmaceutical company, is offering 12,019,230 shares of its common stock in a public offering.
• The company intends to use the net proceeds of approximately $22.9 million for working capital and general corporate purposes, including clinical trials and research and development.
• The offering includes an option for the underwriters to purchase an additional 1,802,884 shares.
• Acurx is focused on developing a new class of small molecule antibiotics targeting Gram-positive bacterial infections.
• Their lead candidate, ibezapolstat, is in Phase 2 clinical trials for C. difficile infections (CDI) and has shown positive results.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced reporting requirements.
• Acurx's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has a history of raising capital through public and private offerings, including an ATM program and registered direct offerings.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol ACXP.
• The last reported sale price of the common stock on March 26, 2024, was $2.08 per share.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has promising clinical trial results and is addressing a critical need, there are significant financial risks and uncertainties about its ability to continue as a going concern. The company is dependent on raising capital to continue operations.

Positives

• The company's lead antibiotic candidate, ibezapolstat, has shown promising clinical trial results.
• The company is targeting a significant market opportunity with antibiotic-resistant infections.
• The company has an early-stage pipeline of antibiotic product candidates with the same mechanism of action.
• The company has access to capital through an ATM program and previous registered direct offerings.
• The company is preparing for an End-of-Phase 2 Meeting with FDA and advancement to Phase 3.

Negatives

• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The company has suffered significant accumulated deficit and had negative operating cash flows.
• The company is dependent upon external sources for financing its operations.
• The company may need substantial additional funding.
• The company's future capital requirements and the period for which it expects its existing resources to support its operations may vary significantly from what it expects.

Risks

• Investing in the company's common stock involves a high degree of risk.
• The company may be unable to raise capital when needed, which could force it to delay, reduce, or eliminate its product development programs.
• The company has broad discretion to determine how to use the funds raised in this offering and may use them in ways that may not enhance its operating results.
• The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern.
• The company may need substantial additional funding, and if it is unable to raise capital when needed, it could be forced to delay, reduce, or eliminate its product development programs or commercialization efforts.
• The company's ability to raise additional funding will depend on financial, economic, and market conditions and other factors, over which it may have no or limited control.
• The company may be unable to obtain and maintain regulatory approval of ibezapolstat and/or its other product candidates.
• The company may be unable to successfully commercialize and market ibezapolstat and/or its other product candidates, if approved.
• The company may be unable to contract with third-party suppliers, manufacturers, and other service providers and their ability to perform adequately.
• The company may be unable to build its own sales and marketing capabilities, or seek collaborative partners, to commercialize ibezapolstat and/or its other product candidates, if approved.
• The company may be unable to retain the continued service of its key professionals and to identify, hire and retain additional qualified professionals.
• The company may be unable to advance product candidates into, and successfully complete, clinical trials.
• The company may be unable to recruit and enroll suitable patients in its clinical trials and the timing of enrollment.
• The company may be unable to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements.
• The company may be unable to prepare, file and prosecute patent applications, maintaining and enforcing its intellectual property rights and defending any intellectual property-related claims.

Future Outlook

The company intends to use the net proceeds from this offering primarily for working capital and other general purposes, including, but not limited to, clinical trials, research and development activities, capital expenditures, investments, acquisitions, should they choose to pursue any, and collaborations. The company expects to partner with a fully-integrated pharmaceutical company for late-stage clinical trials and commercialization or conduct Phase 3 clinical trials prior to such partnership and continue to review partnership opportunities on an ongoing basis up to FDA approval.

Management Comments

• The document does not contain direct quotes from management, but it does state that management will have broad discretion in the application of the net proceeds received from this offering.

Industry Context

Acurx is operating in the biopharmaceutical industry, specifically focused on developing antibiotics to combat antimicrobial resistance, which is a growing global health concern. The company's focus on Gram-positive bacteria and its novel mechanism of action targeting the pol IIIC enzyme differentiate it from other companies in the space. The document mentions that the WHO, CDC, and FDA have identified priority pathogens that require new antibiotics, highlighting the importance of Acurx's work.

Comparison to Industry Standards

• The document mentions that the historical vancomycin cure rate is approximately 81% (Vancocin Prescribing Information, January 2021).
• Acurx believes that, based on the post hoc pooled Phase 2 ibezapolstat Clinical Cure rate of 96% and the historical vancomycin cure rate of approximately 81%, Phase 3 trials would be able to demonstrate the non-inferiority of ibezapolstat to vancomycin.
• However, there can be no assurance that these early-stage, Phase 2 data will predict results in Phase 3 clinical trials.

Stakeholder Impact

• Shareholders will experience dilution as a result of the public offering.
• Employees' job security is tied to the company's ability to secure funding and advance its pipeline.
• Patients could benefit from the development of new antibiotics to combat resistant infections.
• The company's suppliers and creditors are subject to the risk of the company's potential inability to continue as a going concern.

Next Steps

• The company is preparing for an End-of-Phase 2 Meeting with FDA and advancement to Phase 3.
• The company will continue to review partnership opportunities on an ongoing basis up to FDA approval.

Key Dates

Keywords

Acurx Pharmaceuticals, public offering, ibezapolstat, antibiotics, clinical trials, pharmaceutical, ACXP, CDI, DNA pol IIIC inhibitor, antimicrobial resistance